NDAINTRAVENOUSSOLUTION
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GALLIUM GA 68 GOZETOTIDE (gallium ga-68 gozetotide) by Angeles Therapeutics is positron emitting activity [moa]. First approved in 2020.
Drug data last refreshed 4h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GALLIUM GA-68 GOZETOTIDE is a positron-emitting radioactive diagnostic agent administered intravenously as a solution for nuclear imaging. It functions as a diagnostic imaging agent to visualize disease pathology through positron emission tomography (PET). The agent targets specific biological markers to enable detection and localization of disease.
Peak
Peak-stage diagnostic product with moderate competitive pressure (30) suggesting stable but not expanding commercial footprint; team size likely focused on maintenance rather than growth scaling.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GALLIUM GA-68 GOZETOTIDE offers exposure to specialized diagnostic imaging markets and nuclear medicine infrastructure, though limited job posting activity (0 linked positions) suggests a niche product with focused team requirements. Career growth depends on institutional adoption rates and clinical utilization expansion within imaging centers and oncology/neurology departments.
Nuclear Medicine Specialist
Worked on GALLIUM GA 68 GOZETOTIDE at Angeles Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.